These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 2468976)

  • 1. Risk factors in hypertension.
    Kannel WB
    J Cardiovasc Pharmacol; 1989; 13 Suppl 1():S4-10. PubMed ID: 2468976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrated view of hypertension.
    Kannel WB
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():3-8. PubMed ID: 2607526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of multiple risk factors on the hazard of hypertension.
    Kannel WB
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S53-7. PubMed ID: 11527137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension, hypertrophy, and the occurrence of cardiovascular disease.
    Kannel WB
    Am J Med Sci; 1991 Oct; 302(4):199-204. PubMed ID: 1833977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension. Relationship with other risk factors.
    Kannel WB
    Drugs; 1986; 31 Suppl 1():1-11. PubMed ID: 3720567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure.
    Kannel WB
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():199-212. PubMed ID: 9211012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
    Bang CN; Devereux RB; Okin PM
    J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension as a risk factor for cardiac events--epidemiologic results of long-term studies.
    Kannel WB
    J Cardiovasc Pharmacol; 1993; 21 Suppl 2():S27-37. PubMed ID: 7692148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potency of vascular risk factors as the basis for antihypertensive therapy.
    Kannel WB
    Eur Heart J; 1992 Dec; 13 Suppl G():34-42. PubMed ID: 1486903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical heterogeneity of hypertension.
    Kannel WB
    Am J Hypertens; 1991 Mar; 4(3 Pt 1):283-7. PubMed ID: 2043309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.
    Bang CN; Soliman EZ; Simpson LM; Davis BR; Devereux RB; Okin PM;
    Am J Hypertens; 2017 Sep; 30(9):914-922. PubMed ID: 28430947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
    de Simone G; Olsen MH; Wachtell K; Hille DA; Dahlöf B; Ibsen H; Kjeldsen SE; Lyle PA; Devereux RB
    J Hum Hypertens; 2007 Aug; 21(8):625-32. PubMed ID: 17476291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
    Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
    J Hypertens; 2012 Apr; 30(4):802-10; discussion 810. PubMed ID: 22343536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
    Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
    Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
    Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B;
    Ann Intern Med; 2007 Sep; 147(5):311-9. PubMed ID: 17785486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
    Kjeldsen SE; Berge E; Bangalore S; Messerli FH; Mancia G; Holzhauer B; Hua TA; Zappe D; Zanchetti A; Weber MA; Julius S
    Blood Press; 2016; 25(2):83-92. PubMed ID: 26511535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension and other risk factors in coronary heart disease.
    Kannel WB
    Am Heart J; 1987 Oct; 114(4 Pt 2):918-25. PubMed ID: 3661384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.